Drugs / Biphasic insulin aspart 70/30
Biphasic insulin aspart 70/30
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT00118963 Comparator | Jan 2003 → Feb 2006 | type 2 diabetes mellitus | Steno Diabetes Center Copenhagen | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Biphasic insulin aspart 70/30 | “All patients also received biphasic insulin aspart 70/30 (30% soluble insulin aspart and 70% intermediate acting insulin aspart) 6 units once a day before dinner for 12 months.” PMID 19900993 ↗ Nov 2009 |
| Known as | Insulin BIAsp30 | “Insulin BIAsp30 (Novolog 70/30)” NCT00118963 ↗ |
| Known as | Novolog 70/30 | “Insulin BIAsp30 (Novolog 70/30)” NCT00118963 ↗ |
| Route | Subcutaneous | “Subcutaneous injection.” NCT00118963 ↗ |